-
★
Antigenerbsünde
(Hinzugefügt: 05.06.2022 um 15:29 Uhr)
https://de.wikipedia.org/wiki/Antigenerbs%C3%BCnde
-
★
Omicron breakthrough infection drives cross-variant neutralization and memory B cell formation
(Hinzugefügt: 03.04.2022 um 17:24 Uhr)
https://www.biorxiv.org/content/10.1101/2022.04.01.486695v1
-
★
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
(Hinzugefügt: 11.03.2022 um 11:23 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2119451
-
★
OMIKRON-VARIANTE: WIE GUT SCHÜTZEN COVID-19-IMPFSTOFFE VOR HOSPITALISIERUNGEN?
(Hinzugefügt: 19.02.2022 um 13:32 Uhr)
https://www.arznei-telegramm.de/html/2022_02/2202009_02.html
-
★
Reported in vitro Therapeutic Activity
(Hinzugefügt: 18.12.2021 um 14:44 Uhr)
https://opendata.ncats.nih.gov/variant/activity
-
Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by 3 doses of BNT162b2 vaccine or BA.1 infection
(Hinzugefügt: 24.06.2022 um 09:35 Uhr)
https://www.biorxiv.org/content/10.1101/2022.06.05.494889v2
-
Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure
(Hinzugefügt: 24.06.2022 um 09:07 Uhr)
https://www.science.org/doi/10.1126/science.abq1841
-
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
(Hinzugefügt: 24.06.2022 um 07:31 Uhr)
https://www.nature.com/articles/s41586-022-04980-y
-
Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection
(Hinzugefügt: 24.06.2022 um 07:11 Uhr)
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00410-8/fulltext
-
Delineating antibody escape from Omicron sublineages
(Hinzugefügt: 06.06.2022 um 08:56 Uhr)
https://www.biorxiv.org/content/10.1101/2022.04.06.487257v2
-
Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes
(Hinzugefügt: 06.06.2022 um 08:50 Uhr)
https://www.science.org/doi/10.1126/sciimmunol.abq2427?cookieSet=1
-
Delineating antibody escape from Omicron sublineages
(Hinzugefügt: 05.06.2022 um 15:54 Uhr)
https://www.biorxiv.org/content/10.1101/2022.04.06.487257v2
-
Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein
(Hinzugefügt: 05.06.2022 um 15:26 Uhr)
https://pubmed.ncbi.nlm.nih.gov/33909660/
-
Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants
(Hinzugefügt: 27.05.2022 um 08:08 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2205019?query=featured_coronavirus
-
Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum
(Hinzugefügt: 25.05.2022 um 15:29 Uhr)
https://www.biorxiv.org/content/10.1101/2022.05.21.492554v1
-
Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the SARS-CoV-2 BA.1 and BA.2 Omicron variants
(Hinzugefügt: 13.05.2022 um 08:34 Uhr)
https://www.cell.com/med/fulltext/S2666-6340(22)00179-9
-
Antibody Evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 and BA.3 Sub-lineages
(Hinzugefügt: 13.05.2022 um 07:14 Uhr)
https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(22)00243-8
-
Bundesregierung: Omikron-Impfstoff wohl im Herbst einsatzbereit
(Hinzugefügt: 26.04.2022 um 13:37 Uhr)
https://www.aerzteblatt.de/nachrichten/133473/Bundesregierung-Omikron-Impfstoff-wohl-im-Herbst-einsatzbereit
-
Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination
(Hinzugefügt: 03.04.2022 um 18:08 Uhr)
https://wwwnc.cdc.gov/eid/article/28/6/22-0503_article
-
Defining the risk of SARS-CoV-2 variants on immune protection
(Hinzugefügt: 03.04.2022 um 17:35 Uhr)
https://www.nature.com/articles/s41586-022-04690-5_reference.pdf
-
Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants
(Hinzugefügt: 22.03.2022 um 11:34 Uhr)
https://www.cell.com/cell/fulltext/S0092-8674(22)00329-4#relatedArticles
-
Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines
(Hinzugefügt: 18.03.2022 um 09:31 Uhr)
https://www.biorxiv.org/content/10.1101/2022.03.15.484542v1
-
Omicron variant Spike-specific antibody binding and Fc activity is preserved in recipients of mRNA or inactivated COVID-19 vaccines
(Hinzugefügt: 16.03.2022 um 14:03 Uhr)
https://www.science.org/doi/10.1126/scitranslmed.abn9243
-
Omicron-specific mRNA vaccine induced potent neutralizing antibody against Omicron but not other SARS-CoV-2 variants
(Hinzugefügt: 17.02.2022 um 06:22 Uhr)
https://www.biorxiv.org/content/10.1101/2022.01.31.478406v1
-
Omicron-targeted vaccines do no better than original jabs in early tests
(Hinzugefügt: 16.02.2022 um 13:48 Uhr)
https://www.nature.com/articles/d41586-022-00003-y
-
SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons
(Hinzugefügt: 24.01.2022 um 20:13 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2119236
-
SARS-CoV-2 Omicron Neutralization After Heterologous Vaccine Boosting
(Hinzugefügt: 24.01.2022 um 19:58 Uhr)
https://www.medrxiv.org/content/10.1101/2022.01.13.22268861v1
-
SARS-CoV-2 vaccination induces immunological memory able to cross-recognize variants from Alpha to Omicron
(Hinzugefügt: 30.12.2021 um 11:35 Uhr)
https://www.biorxiv.org/content/10.1101/2021.12.28.474333v1
-
Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations
(Hinzugefügt: 23.12.2021 um 20:11 Uhr)
https://www.medrxiv.org/content/10.1101/2021.12.21.21267898v1
-
Activity of convalescent and vaccine serum against a B.1.1.529 variant SARS-CoV-2 isolate
(Hinzugefügt: 23.12.2021 um 20:08 Uhr)
https://www.medrxiv.org/content/10.1101/2021.12.20.21268134v1
-
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant
(Hinzugefügt: 23.12.2021 um 19:43 Uhr)
https://www.biorxiv.org/content/10.1101/2021.12.20.473557v1
-
Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies
(Hinzugefügt: 21.12.2021 um 12:26 Uhr)
https://cdn.who.int/media/docs/default-source/blue-print/marek-widera_c19_whoconsulation_15dec2021.pdf
-
Reduced sera neutralization to Omicron SARS-CoV-2 by both inactivated and protein subunit vaccines and the convalescents
(Hinzugefügt: 20.12.2021 um 16:38 Uhr)
https://www.biorxiv.org/content/10.1101/2021.12.16.472391v1
-
Plasma neutralization properties of the SARS-CoV-2 Omicron variant
(Hinzugefügt: 18.12.2021 um 15:00 Uhr)
https://www.medrxiv.org/content/10.1101/2021.12.12.21267646v1
-
Human serum from SARS-CoV-2 vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant
(Hinzugefügt: 18.12.2021 um 14:59 Uhr)
https://www.medrxiv.org/content/10.1101/2021.12.10.21267523v2
-
Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
(Hinzugefügt: 17.12.2021 um 14:05 Uhr)
https://www.medrxiv.org/content/10.1101/2021.12.14.21267615v1
-
Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients
(Hinzugefügt: 17.12.2021 um 14:00 Uhr)
https://www.medrxiv.org/content/10.1101/2021.12.13.21267668v1
-
COVID-19: Laborstudie bestätigt geringe Schutzwirkung der Impfung gegen Omikron
(Hinzugefügt: 17.12.2021 um 13:54 Uhr)
https://www.aerzteblatt.de/nachrichten/130078/COVID-19-Laborstudie-bestaetigt-geringe-Schutzwirkung-der-Impfung-gegen-Omikron
-
PEI-Präsident: Omikron-Impfstoffe in „drei bis vier Monaten“
(Hinzugefügt: 17.12.2021 um 13:53 Uhr)
https://www.aerzteblatt.de/nachrichten/130093/PEI-Praesident-Omikron-Impfstoffe-in-drei-bis-vier-Monaten
-
Universal Coronavirus Vaccines — An Urgent Need
(Hinzugefügt: 17.12.2021 um 13:21 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMp2118468
-
What does Omicron mean for future COVID-19 vaccinations?
(Hinzugefügt: 17.12.2021 um 13:20 Uhr)
https://www.science.org/content/article/what-does-omicron-mean-future-covid-19-vaccinations
-
SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern
(Hinzugefügt: 17.12.2021 um 13:18 Uhr)
https://www.medrxiv.org/content/10.1101/2021.12.14.21267772v1.full.pdf
-
Preliminary experimental data on T cell cross-reactivity to Omicron
(Hinzugefügt: 17.12.2021 um 12:22 Uhr)
https://cdn.who.int/media/docs/default-source/blue-print/wendy-burgers_c19_whoconsulation_15dec2021.pdf?sfvrsn=2a2a7479_7
-
Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization
(Hinzugefügt: 17.12.2021 um 10:02 Uhr)
https://www.biorxiv.org/content/10.1101/2021.12.14.472630v1.full.pdf
-
Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
(Hinzugefügt: 13.12.2021 um 10:37 Uhr)
https://khub.net/documents/135939561/430986542/Effectiveness+of+COVID-19+vaccines+against+Omicron+variant+of+concern.pdf/f423c9f4-91cb-0274-c8c5-70e8fad50074
-
Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum
(Hinzugefügt: 13.12.2021 um 10:25 Uhr)
https://www.medrxiv.org/content/10.1101/2021.12.10.21267534v1
-
SARS-CoV-2 B.1.1.529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent individuals
(Hinzugefügt: 13.12.2021 um 10:25 Uhr)
https://www.medrxiv.org/content/10.1101/2021.12.08.21267491v1
-
Estimates of reduced vaccine effectiveness against hospitalization, infection, transmission and symptomatic disease of a new SARS-CoV-2 variant, Omicron (B.1.1.529), using neutralizing antibody titers
(Hinzugefügt: 13.12.2021 um 10:18 Uhr)
https://www.medrxiv.org/content/10.1101/2021.12.10.21267594v2
-
Mechanisms of SARS-CoV-2 Evolution Revealing Vaccine-Resistant Mutations in Europe and America
(Hinzugefügt: 09.12.2021 um 17:51 Uhr)
https://pubs.acs.org/doi/10.1021/acs.jpclett.1c03380
-
SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection
(Hinzugefügt: 09.12.2021 um 16:58 Uhr)
https://www.ahri.org/wp-content/uploads/2021/12/MEDRXIV-2021-267417v1-Sigal.pdf
-
Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies
(Hinzugefügt: 09.12.2021 um 16:48 Uhr)
https://www.medrxiv.org/content/10.1101/2021.12.07.21267432v2
-
Omicron likely to weaken COVID vaccine protection
(Hinzugefügt: 09.12.2021 um 16:42 Uhr)
https://www.nature.com/articles/d41586-021-03672-3
-
Omikron: Labortests deuten auf abgeschwächte Wirkung von Impfstoffen hin
(Hinzugefügt: 09.12.2021 um 08:24 Uhr)
https://www.aerzteblatt.de/nachrichten/129865/Omikron-Labortests-deuten-auf-abgeschwaechte-Wirkung-von-Impfstoffen-hin
-
Omikron: Zulassung angepasster Impfstoffe könnte bis zu vier Monate dauern
(Hinzugefügt: 01.12.2021 um 18:13 Uhr)
https://www.aerzteblatt.de/nachrichten/129533/Omikron-Zulassung-angepasster-Impfstoffe-koennte-bis-zu-vier-Monate-dauern
-
Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines
(Hinzugefügt: 01.12.2021 um 18:07 Uhr)
https://www.biorxiv.org/content/10.1101/2021.11.24.469906v1
-
Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains
(Hinzugefügt: 01.12.2021 um 18:04 Uhr)
https://www.science.org/doi/10.1126/scitranslmed.abm3302
-
Biontech arbeitet an Impfstoffanpassung
(Hinzugefügt: 30.11.2021 um 16:27 Uhr)
https://www.aerzteblatt.de/nachrichten/129541/Biontech-arbeitet-an-Impfstoffanpassung
-
High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape
(Hinzugefügt: 28.11.2021 um 15:19 Uhr)
https://www.nature.com/articles/s41586-021-04005-0
-
Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
(Hinzugefügt: 28.11.2021 um 15:14 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-strategy-address-omicron-b11529-sars-cov-2
-
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study
(Hinzugefügt: 25.11.2021 um 19:10 Uhr)
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00648-4/fulltext
-
Increased risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variant compared to Alpha variant in vaccinated individuals
(Hinzugefügt: 25.11.2021 um 12:22 Uhr)
https://www.medrxiv.org/content/10.1101/2021.11.24.21266735v1
-
Low neutralizing antibody titers against the Mu variant of SARS-CoV-2 in BNT162b2 vaccinated individuals
(Hinzugefügt: 20.11.2021 um 10:29 Uhr)
https://www.medrxiv.org/content/10.1101/2021.11.19.21266552v1
-
Neutralisation of the SARS-CoV-2 Delta sub-lineage AY.4.2 and B.1.617.2 + E484K by BNT162b2 mRNA vaccine-elicited sera
(Hinzugefügt: 19.11.2021 um 16:55 Uhr)
https://www.medrxiv.org/content/10.1101/2021.11.08.21266075v3
-
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
(Hinzugefügt: 19.11.2021 um 16:00 Uhr)
https://pubmed.ncbi.nlm.nih.gov/33567448/
-
Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants
(Hinzugefügt: 15.11.2021 um 07:15 Uhr)
https://www.science.org/doi/10.1126/science.abl8506
-
SARS-CoV-2: Mu-Variante aus Südamerika hat Potenzial für Impfdurchbrüche
(Hinzugefügt: 09.11.2021 um 16:00 Uhr)
https://www.aerzteblatt.de/nachrichten/128896/SARS-CoV-2-Mu-Variante-aus-Suedamerika-hat-Potenzial-fuer-Impfdurchbrueche
-
Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum
(Hinzugefügt: 04.11.2021 um 08:42 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2114706
-
Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant
(Hinzugefügt: 04.11.2021 um 08:29 Uhr)
https://www.science.org/doi/10.1126/science.abl9551
-
COVID vaccine makers brace for a variant worse than Delta
(Hinzugefügt: 01.11.2021 um 10:00 Uhr)
https://www.nature.com/articles/d41586-021-02854-3
-
B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination
(Hinzugefügt: 22.10.2021 um 16:24 Uhr)
https://www.cell.com/cell-reports/fulltext/S2211-1247(21)01289-4
-
COVID-19: Impfung schützt Jugendliche und Erwachsene auch vor der Delta-Variante
(Hinzugefügt: 22.10.2021 um 16:20 Uhr)
https://www.aerzteblatt.de/nachrichten/128375/COVID-19-Impfung-schuetzt-Jugendliche-und-Erwachsene-auch-vor-der-Delta-Variante
-
Neutralization of Mu and C.1.2 SARS-CoV-2 Variants by Vaccine-elicited Antibodies in Individuals With and Without Previous History of Infection
(Hinzugefügt: 21.10.2021 um 11:06 Uhr)
https://www.biorxiv.org/content/10.1101/2021.10.19.463727v1
-
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
(Hinzugefügt: 18.10.2021 um 10:11 Uhr)
https://www.science.org/doi/10.1126/science.abm0829
-
Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2
(Hinzugefügt: 18.10.2021 um 10:08 Uhr)
https://www.medrxiv.org/content/10.1101/2021.10.12.21264840v1
-
Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance
(Hinzugefügt: 18.10.2021 um 10:05 Uhr)
https://www.nature.com/articles/s41423-021-00772-y
-
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
(Hinzugefügt: 18.10.2021 um 10:04 Uhr)
https://www.science.org/doi/10.1126/science.abm0829
-
Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021
(Hinzugefügt: 18.10.2021 um 10:02 Uhr)
https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.41.2100920
-
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
(Hinzugefügt: 16.10.2021 um 11:43 Uhr)
https://www.nature.com/articles/s41591-021-01548-7.epdf?sharing_token=o191M-3qr2bFbRNEKAle99RgN0jAjWel9jnR3ZoTv0O7zIK2rOjGcRV-Tyxmyg8iJdfbXkWaY7KQNhv3pi2NkcFqL-EyCDoQ8M6gVcAMwRxh-dkaFid-Dn4lqJ2BmcweoeKcwBOQ3z5NKmrRubog5X6ZTStuy1T0KE7cB3Xmoy0%3D
-
Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity
(Hinzugefügt: 12.10.2021 um 10:32 Uhr)
https://www.nature.com/articles/s41586-021-04085-y
-
Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California
(Hinzugefügt: 06.10.2021 um 06:41 Uhr)
https://www.medrxiv.org/content/10.1101/2021.08.19.21262139v1
-
Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint
(Hinzugefügt: 29.09.2021 um 10:16 Uhr)
https://www.medrxiv.org/content/10.1101/2021.09.23.21263715v1
-
Four SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-CoV-2 variants
(Hinzugefügt: 29.09.2021 um 10:12 Uhr)
https://www.medrxiv.org/content/10.1101/2021.09.27.21264163v1
-
Neutralizing efficacy of vaccines against the SARS-CoV-2 Mu variant
(Hinzugefügt: 27.09.2021 um 09:59 Uhr)
https://www.medrxiv.org/content/10.1101/2021.09.23.21264014v1
-
Efficacy of vaccination against severe COVID-19 in relation to Delta variant and time since second dose: the REACT-SCOT case-control study
(Hinzugefügt: 19.09.2021 um 14:54 Uhr)
https://www.medrxiv.org/content/10.1101/2021.09.12.21263448v1
-
COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants
(Hinzugefügt: 19.09.2021 um 14:36 Uhr)
https://www.cell.com/cell/fulltext/S0092-8674(21)01057-6
-
BNT162b2-Elicited Neutralization of Delta Plus, Lambda, and Other Variants
(Hinzugefügt: 15.09.2021 um 16:04 Uhr)
https://www.biorxiv.org/content/10.1101/2021.09.13.460163v1
-
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
(Hinzugefügt: 15.09.2021 um 14:39 Uhr)
https://www.nature.com/articles/s41586-021-03944-y
-
Vaccines Will Not Produce Worse Variants
(Hinzugefügt: 14.09.2021 um 07:38 Uhr)
https://www.science.org/content/blog-post/vaccines-will-not-produce-worse-variants
-
The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines
(Hinzugefügt: 26.08.2021 um 04:29 Uhr)
https://www.biorxiv.org/content/10.1101/2021.08.22.457114v1
-
Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
(Hinzugefügt: 26.08.2021 um 04:03 Uhr)
https://www.medrxiv.org/content/10.1101/2021.08.18.21262237v1
-
Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021
(Hinzugefügt: 26.08.2021 um 04:02 Uhr)
https://www.cdc.gov/mmwr/volumes/70/wr/mm7034e4.htm
-
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
(Hinzugefügt: 24.08.2021 um 17:21 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2108891
-
Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence
(Hinzugefügt: 24.08.2021 um 17:15 Uhr)
https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v1.full.pdf
-
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar
(Hinzugefügt: 24.08.2021 um 16:59 Uhr)
https://www.medrxiv.org/content/10.1101/2021.08.11.21261885v1
-
Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
(Hinzugefügt: 24.08.2021 um 16:28 Uhr)
https://www.ndm.ox.ac.uk/files/coronavirus/covid-19-infection-survey/finalfinalcombinedve20210816.pdf
-
Vaccines still effective against Delta variant of concern, says Oxford-led study of the COVID-19 Infections Survey
(Hinzugefügt: 24.08.2021 um 16:16 Uhr)
https://www.ox.ac.uk/news/2021-08-19-vaccines-still-effective-against-delta-variant-concern-says-oxford-led-study-covid-0
-
Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021
(Hinzugefügt: 24.08.2021 um 15:18 Uhr)
https://www.cdc.gov/mmwr/volumes/70/wr/mm7034e2.htm
-
Studie: Impfschutz vor Delta-Infektion ist nach Astrazeneca zunächst schwächer
(Hinzugefügt: 24.08.2021 um 15:09 Uhr)
https://www.aerzteblatt.de/nachrichten/126530/Studie-Impfschutz-vor-Delta-Infektion-ist-nach-Astrazeneca-zunaechst-schwaecher
-
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
(Hinzugefügt: 14.08.2021 um 08:58 Uhr)
https://science.sciencemag.org/content/early/2021/08/11/science.abj4176.full
-
Lambda Variant of COVID-19 Might Be Resistant to Vaccines
(Hinzugefügt: 07.08.2021 um 15:59 Uhr)
https://www.infectioncontroltoday.com/view/lambda-variant-of-covid-19-might-be-resistant-to-vaccines
-
REACT-1 round 13 final report: exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant in England during May to July 2021
(Hinzugefügt: 06.08.2021 um 11:34 Uhr)
https://spiral.imperial.ac.uk/handle/10044/1/90800
-
Coronavirus-Mutation Lambda-Variante könnte Immunschutz abschwächen
(Hinzugefügt: 04.08.2021 um 08:52 Uhr)
https://www.spiegel.de/wissenschaft/medizin/coronavirus-mutation-ist-die-lambda-variante-gegen-corona-impfstoffe-resistent-a-adc2fe93-b25b-4b17-a836-b57227911933
-
Rates of SARS-CoV-2 transmission and vaccination impact the fate of vaccine-resistant strains
(Hinzugefügt: 03.08.2021 um 10:00 Uhr)
https://www.nature.com/articles/s41598-021-95025-3
-
Biontech und Astrazeneca: Impfstoffwirksamkeit gegen Delta nur leicht abgeschwächt
(Hinzugefügt: 27.07.2021 um 19:29 Uhr)
https://www.aerzteblatt.de/nachrichten/125802/Biontech-und-Astrazeneca-Impfstoffwirksamkeit-gegen-Delta-nur-leicht-abgeschwaecht
-
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
(Hinzugefügt: 22.07.2021 um 09:37 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2108891
-
Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants
(Hinzugefügt: 21.07.2021 um 13:16 Uhr)
https://www.biorxiv.org/content/10.1101/2021.07.19.452771v1?fbclid=IwAR28pbVCJdPsTwufXAljmx_vCDl6bQR989OFwxqDwVhZjK64xlR44UkwtbY
-
Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France
(Hinzugefügt: 20.07.2021 um 10:56 Uhr)
https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(21)00148-4/fulltext
-
Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity in uninfected and previously infected individuals
(Hinzugefügt: 19.07.2021 um 11:49 Uhr)
https://www.medrxiv.org/content/10.1101/2021.07.14.21260307v1
-
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
(Hinzugefügt: 17.07.2021 um 13:22 Uhr)
https://www.nature.com/articles/s41591-021-01449-9
-
'Pfizer COVID vaccine significantly less effective against Delta variant'
(Hinzugefügt: 17.07.2021 um 13:20 Uhr)
https://www.jpost.com/breaking-news/for-first-time-since-march-855-new-coronavirus-cases-in-israel-674084
-
Pfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant
(Hinzugefügt: 13.07.2021 um 07:09 Uhr)
https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-provide-update-booster-program-light-delta/
-
Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study
(Hinzugefügt: 09.07.2021 um 19:05 Uhr)
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00129-4/fulltext
-
SARS-CoV-2 Lambda Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies and Convalescent Serum
(Hinzugefügt: 09.07.2021 um 18:47 Uhr)
https://www.biorxiv.org/content/10.1101/2021.07.02.450959v1
-
SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants
(Hinzugefügt: 09.07.2021 um 18:46 Uhr)
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003656
-
Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants
(Hinzugefügt: 09.07.2021 um 18:45 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2107799
-
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
(Hinzugefügt: 09.07.2021 um 18:32 Uhr)
https://www.nature.com/articles/s41586-021-03777-9
-
Studie: Geimpfte und Rekonvaleszente vor Delta und Kappa geschützt
(Hinzugefügt: 09.07.2021 um 18:20 Uhr)
https://www.aerzteblatt.de/nachrichten/125443/Studie-Geimpfte-und-Rekonvaleszente-vor-Delta-und-Kappa-geschuetzt
-
Effectiveness of COVID-19 vaccines against variants of concern, Canada
(Hinzugefügt: 05.07.2021 um 11:27 Uhr)
https://www.medrxiv.org/content/10.1101/2021.06.28.21259420v1
-
Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine breakthrough infections
(Hinzugefügt: 05.07.2021 um 11:26 Uhr)
https://www.medrxiv.org/content/10.1101/2021.06.28.21258780v1
-
SARS-CoV-2: Astrazeneca-Impfstoff erzeugt weniger Antikörper gegen Delta-Variante als mRNA-Vakzine
(Hinzugefügt: 04.07.2021 um 06:19 Uhr)
https://www.aerzteblatt.de/nachrichten/125191/SARS-CoV-2-Astrazeneca-Impfstoff-erzeugt-weniger-Antikoerper-gegen-Delta-Variante-als-mRNA-Vakzine
-
Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern
(Hinzugefügt: 03.07.2021 um 17:51 Uhr)
https://www.biorxiv.org/content/10.1101/2021.07.01.450707v1
-
SARS-CoV-2 Variants and Vaccines
(Hinzugefügt: 30.06.2021 um 15:32 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMsr2105280
-
SARS-CoV-2 B.1.617.2 Delta variant emergence and vaccine breakthrough
(Hinzugefügt: 30.06.2021 um 15:30 Uhr)
https://www.researchsquare.com/article/rs-637724/v1
-
Pfizer says COVID vaccine is highly effective against Delta variant
(Hinzugefügt: 30.06.2021 um 15:22 Uhr)
https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-says-covid-vaccine-highly-effective-against-delta-variant-2021-06-24/
-
First COVID-19 variant vaccine AZD2816 Phase II/III trial participants vaccinated
(Hinzugefügt: 30.06.2021 um 15:01 Uhr)
https://www.astrazeneca.com/media-centre/press-releases/2021/first-covid-19-variant-vaccine-azd2816-phase-ii-iii-trial-participants-vaccinated.html
-
Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants
(Hinzugefügt: 30.06.2021 um 14:57 Uhr)
https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1
-
Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination
(Hinzugefügt: 30.06.2021 um 14:54 Uhr)
https://www.medrxiv.org/content/10.1101/2021.06.23.21259327v1
-
Moderna Provides a Clinical Update on the Neutralizing Activity of its COVID-19 Vaccine on Emerging Variants Including the Delta Variant First Identified in India
(Hinzugefügt: 30.06.2021 um 14:54 Uhr)
https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-clinical-update-neutralizing-activity-its-covid/
-
AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC
(Hinzugefügt: 30.06.2021 um 14:43 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01462-8/fulltext
-
Experimenteller Impfstoff mit chimären Spikes könnte vor mehreren Coronaviren und seinen Varianten schützen
(Hinzugefügt: 23.06.2021 um 18:01 Uhr)
https://www.aerzteblatt.de/nachrichten/124984/Experimenteller-Impfstoff-mit-chimaeren-Spikes-koennte-vor-mehreren-Coronaviren-und-seinen-Varianten-schuetzen
-
Coronavirus: Any third-dose vaccine will need to be variant-proof, Task Force says
(Hinzugefügt: 21.06.2021 um 13:13 Uhr)
https://www.brusselstimes.com/news/belgium-all-news/174532/coronavirus-any-third-dose-vaccine-will-need-to-be-variant-proof-task-force-says/
-
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness
(Hinzugefügt: 20.06.2021 um 18:04 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01358-1/fulltext
-
COVID-19 Vaccine AstraZeneca effective against Delta (‘Indian’) variant
(Hinzugefügt: 20.06.2021 um 17:51 Uhr)
https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-effective-against-delta-indian-variant.html
-
Impfung schützt vor Hospitalisierung durch Delta-Variante
(Hinzugefügt: 20.06.2021 um 17:38 Uhr)
https://www.aerzteblatt.de/nachrichten/124716/Impfung-schuetzt-vor-Hospitalisierung-durch-Delta-Variante
-
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2mRNA-vaccinated individuals
(Hinzugefügt: 20.06.2021 um 10:42 Uhr)
https://www.nature.com/articles/s41591-021-01413-7.epdf?sharing_token=aSr91qIS6rlWNoKywzXyu9RgN0jAjWel9jnR3ZoTv0PsVf7u7EP7Hz2RsahIREcgB-FGHu_LpsHVW8xGy9l_2ndTewbxX6v2uGyHSGBbpz7eJ1l_b7LhXgys2HEPrDacetDXmexr6RLALLIEA5gQWr0EdrYleNNZL4irtGceal4%3D
-
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
(Hinzugefügt: 20.06.2021 um 10:37 Uhr)
https://www.cell.com/cell/fulltext/S0092-8674(21)00755-8
-
Johnson& Johnson: Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
(Hinzugefügt: 11.06.2021 um 06:51 Uhr)
https://www.nature.com/articles/s41586-021-03681-2
-
Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein
(Hinzugefügt: 11.06.2021 um 06:47 Uhr)
https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0250780
-
Astra Zeneca/ Beta: The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 B.1.351 and other variants of concern in preclinical studies.
(Hinzugefügt: 11.06.2021 um 06:46 Uhr)
https://www.biorxiv.org/content/10.1101/2021.06.08.447308v1
-
Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein
(Hinzugefügt: 11.06.2021 um 06:45 Uhr)
https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0250780
-
Johnson& Johnson/ Beta: New Evidence Suggests COVID-19 Vaccines Remain Effective Against Variants
(Hinzugefügt: 11.06.2021 um 06:44 Uhr)
https://www.npr.org/sections/health-shots/2021/06/09/1004738276/new-evidence-suggests-covid-19-vaccines-remain-effective-against-variants
-
BioNTech/ Delta: BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants
(Hinzugefügt: 11.06.2021 um 06:41 Uhr)
https://www.nature.com/articles/s41586-021-03693-y
-
BioNTech/ Beta/ Delta: Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
(Hinzugefügt: 09.06.2021 um 19:09 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01290-3/fulltext
-
Moderna Beta/ Gamma: Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster
(Hinzugefügt: 07.06.2021 um 08:11 Uhr)
https://www.medrxiv.org/content/10.1101/2021.05.05.21256716v1
-
Novavax/ Beta: Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
(Hinzugefügt: 07.06.2021 um 08:10 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2103055?query=featured_coronavirus
-
BioNTech/ Alpha: Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
(Hinzugefügt: 07.06.2021 um 08:09 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00947-8/fulltext
-
Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination
(Hinzugefügt: 06.06.2021 um 14:50 Uhr)
https://www.medrxiv.org/content/10.1101/2021.05.26.21257441v1
-
COVID-19: Pfizer jab recipients have lower antibodies targeting Indian variant, study suggests
(Hinzugefügt: 06.06.2021 um 14:35 Uhr)
https://news.sky.com/story/covid-19-people-who-have-had-pfizer-vaccine-have-lower-antibodies-targeting-indian-variant-study-suggests-12324395
-
Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals
(Hinzugefügt: 28.05.2021 um 08:24 Uhr)
https://www.biorxiv.org/content/10.1101/2021.05.26.445838v1
-
Covid-19: Single vaccine dose is 33% effective against variant from India, data show
(Hinzugefügt: 28.05.2021 um 08:19 Uhr)
https://www.bmj.com/content/373/bmj.n1346
-
SARS-CoV-2: Impfstoffe gegen indische Variante B.1.617.2 wohl etwas schwächer wirksam
(Hinzugefügt: 27.05.2021 um 15:47 Uhr)
https://www.aerzteblatt.de/nachrichten/124090/SARS-CoV-2-Impfstoffe-gegen-indische-Variante-B-1-617-2-wohl-etwas-schwaecher-wirksam
-
Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State
(Hinzugefügt: 26.05.2021 um 08:50 Uhr)
https://www.medrxiv.org/content/10.1101/2021.05.23.21257679v1
-
SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees
(Hinzugefügt: 26.05.2021 um 08:48 Uhr)
https://immunology.sciencemag.org/content/6/59/eabj1750.full
-
Effectiveness of COVID-19 vaccines against the B.1.617.2 variant
(Hinzugefügt: 25.05.2021 um 14:12 Uhr)
https://www.medrxiv.org/content/10.1101/2021.05.22.21257658v1
-
SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern
(Hinzugefügt: 25.05.2021 um 13:50 Uhr)
https://www.nature.com/articles/s41392-021-00623-2
-
Current COVID vaccines appear protective against variants, WHO Europe says
(Hinzugefügt: 22.05.2021 um 17:53 Uhr)
https://www.reuters.com/business/healthcare-pharmaceuticals/current-covid-vaccines-appear-protective-against-variants-who-europe-says-2021-05-20/?taid=60a65650a32ba4000137c73f&utm_campaign=trueAnthem:+Trending+Content&utm_medium=trueAnthem&utm_source=twitt
-
The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies.
(Hinzugefügt: 17.05.2021 um 09:47 Uhr)
https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1
-
New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications
(Hinzugefügt: 13.05.2021 um 17:08 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2100362
-
European regulator 'pretty confident' mRNA COVID vaccines work against Indian variant
(Hinzugefügt: 13.05.2021 um 17:05 Uhr)
https://www.euronews.com/2021/05/13/european-regulator-pretty-confident-mrna-covid-vaccines-work-against-indian-variant
-
Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
(Hinzugefügt: 11.05.2021 um 07:06 Uhr)
https://www.nature.com/articles/s41586-021-03594-0_reference.pdf
-
EU-Großeinkauf bei BioNTech/Pfizer
(Hinzugefügt: 08.05.2021 um 12:42 Uhr)
https://www.tagesschau.de/ausland/europa/eu-impfstoff-corona-101.html
-
SARS-CoV-2: Neuer Impfstoff erzielt Immunität gegen südafrikanische Variante
(Hinzugefügt: 08.05.2021 um 12:25 Uhr)
https://www.aerzteblatt.de/nachrichten/123632/SARS-CoV-2-Neuer-Impfstoff-erzielt-Immunitaet-gegen-suedafrikanische-Variante
-
Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster
(Hinzugefügt: 07.05.2021 um 06:31 Uhr)
https://www.medrxiv.org/content/10.1101/2021.05.05.21256716v1
-
Risk from virus variants remains after first Pfizer COVID-19 vaccine, UK study finds
(Hinzugefügt: 02.05.2021 um 02:58 Uhr)
https://www.reuters.com/business/healthcare-pharmaceuticals/risk-virus-variants-remains-after-first-pfizer-covid-19-vaccine-uk-study-finds-2021-04-30/
-
«Die Schweiz muss jetzt Impfstoff für die nächsten Jahre bestellen»
(Hinzugefügt: 24.04.2021 um 06:25 Uhr)
https://www.20min.ch/story/die-schweiz-muss-jetzt-impfstoff-fuer-die-naechsten-jahre-bestellen-508091064984
-
Coronavirus Variants and Vaccines
(Hinzugefügt: 21.04.2021 um 06:06 Uhr)
https://edhub.ama-assn.org/jn-learning/video-player/18599731
-
SARS-CoV-2 wird dauerhaft bleiben – Neue Impfstoffe erforderlich
(Hinzugefügt: 19.04.2021 um 09:10 Uhr)
https://www.heilpraxisnet.de/naturheilpraxis/sars-cov-2-wird-dauerhaft-bleiben-neue-impfstoffe-erforderlich-20210419537035/
-
BNT162b2 Vaccination Effectively Prevents the Rapid Rise of SARS-CoV-2 Variant B.1.1.7 in high risk populations in Israel
(Hinzugefügt: 19.04.2021 um 06:39 Uhr)
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00080-X
-
Pfizer-Chef: Wahrscheinlich dritte und jährliche Impfdosis notwendig
(Hinzugefügt: 17.04.2021 um 10:01 Uhr)
https://www.aerzteblatt.de/nachrichten/123033/Pfizer-Chef-Wahrscheinlich-dritte-und-jaehrliche-Impfdosis-notwendig
-
The Balancing Role of Distribution Speed against Varying Efficacy Levels of COVID-19 Vaccines under Variants
(Hinzugefügt: 16.04.2021 um 12:31 Uhr)
https://www.medrxiv.org/content/10.1101/2021.04.09.21255217v1
-
How effective are COVID vaccines against these variants?
(Hinzugefügt: 12.04.2021 um 18:03 Uhr)
https://www.silive.com/coronavirus/2021/04/how-effective-are-covid-vaccines-against-these-variants.html
-
South African variant can 'break through' Pfizer vaccine, Israeli study says
(Hinzugefügt: 11.04.2021 um 06:35 Uhr)
https://www.reuters.com/article/us-health-coronavirus-israel-study-idUSKBN2BX0JZ
-
Why we need booster vaccines against variants to help end the pandemic
(Hinzugefügt: 10.04.2021 um 12:05 Uhr)
https://www.nationalgeographic.co.uk/science-and-technology/2021/04/why-we-need-booster-vaccines-against-variants-to-help-end-the
-
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals
(Hinzugefügt: 10.04.2021 um 06:06 Uhr)
https://www.medrxiv.org/content/10.1101/2021.04.06.21254882v1
-
SARS-CoV-2 immune evasion by variant B.1.427/B.1.429
(Hinzugefügt: 09.04.2021 um 05:55 Uhr)
https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1
-
Scientists Race To Develop Next Generation Of COVID Vaccines
(Hinzugefügt: 08.04.2021 um 06:26 Uhr)
https://www.npr.org/sections/health-shots/2021/04/06/984486776/scientists-race-to-develop-next-generation-of-covid-vaccines?t=1617863147084
-
Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
(Hinzugefügt: 08.04.2021 um 06:13 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2103740
-
Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization
(Hinzugefügt: 07.04.2021 um 07:06 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2103022
-
Driving potent neutralization of a SARS-CoV-2 Variant of Concern with a heterotypic boost
(Hinzugefügt: 06.04.2021 um 06:54 Uhr)
https://www.biorxiv.org/content/10.1101/2021.04.03.438330v1
-
Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination
(Hinzugefügt: 03.04.2021 um 06:10 Uhr)
https://www.nature.com/articles/s41577-021-00544-9.pdf
-
COVID research updates: New coronavirus variants spur multi-talented antibody response
(Hinzugefügt: 30.03.2021 um 19:25 Uhr)
https://www.nature.com/articles/d41586-020-00502-w
-
Sorge über mutierte GB-Variante in Tirol
(Hinzugefügt: 30.03.2021 um 19:05 Uhr)
https://orf.at/stories/3207129/
-
Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies
(Hinzugefügt: 30.03.2021 um 08:32 Uhr)
https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
-
Existing vaccines may protect against the Brazilian coronavirus variant
(Hinzugefügt: 29.03.2021 um 06:20 Uhr)
https://www.ox.ac.uk/news/2021-03-18-existing-vaccines-may-protect-against-brazilian-coronavirus-variant
-
Covid-19: variants and vaccination
(Hinzugefügt: 26.03.2021 um 20:49 Uhr)
https://www.bmj.com/content/372/bmj.n771
-
Immunescape: B.1.352 ist der wahrscheinlichste Kandidat
(Hinzugefügt: 26.03.2021 um 07:47 Uhr)
https://www.aerzteblatt.de/nachrichten/122353/Immunescape-B-1-352-ist-der-wahrscheinlichste-Kandidat
-
New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications
(Hinzugefügt: 25.03.2021 um 06:32 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2100362
-
High levels of Covid infection right now could mean problems for vaccines later, ex-CDC chief says
(Hinzugefügt: 23.03.2021 um 15:51 Uhr)
https://edition.cnn.com/2021/03/23/health/us-coronavirus-tuesday/index.html
-
Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection
(Hinzugefügt: 23.03.2021 um 15:45 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00468-2/fulltext#.YFm3WJ41tPc.twitter
-
New SARS-CoV-2 variants: How can vaccines be adapted?
(Hinzugefügt: 23.03.2021 um 09:49 Uhr)
https://www.medicalnewstoday.com/articles/new-sars-cov-2-variants-how-can-vaccines-be-adapted
-
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
(Hinzugefügt: 21.03.2021 um 19:12 Uhr)
https://www.cell.com/cell/fulltext/S0092-8674(21)00367-6?rss=yes
-
SARS-CoV-2: Impfstoffe zeigen nur leicht abgeschwächte Wirkung gegen Virusvariante aus Brasilien
(Hinzugefügt: 19.03.2021 um 20:26 Uhr)
https://www.aerzteblatt.de/nachrichten/122229/SARS-CoV-2-Impfstoffe-zeigen-nur-leicht-abgeschwaechte-Wirkung-gegen-Virusvariante-aus-Brasilien
-
Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination
(Hinzugefügt: 19.03.2021 um 20:23 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2777898
-
Forscher befürchtet impfresistentes Virus »Brasilien ist eine Gefahr für die Weltgesundheit«
(Hinzugefügt: 19.03.2021 um 08:49 Uhr)
https://www.spiegel.de/politik/ausland/coronavirus-in-manaus-amazonas-forscher-befuerchtet-impfresistentes-virus-a-cfd722fa-c494-4971-969b-982cf362a837?sara_ecid=soci_upd_KsBF0AFjflf0DZCxpPYDCQgO1dEMph
-
COVID-19 Vaccines vs Variants—Determining How Much Immunity Is Enough
(Hinzugefügt: 19.03.2021 um 08:36 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2777785
-
Virus variants found to be deadlier, more contagious; some may thwart vaccines
(Hinzugefügt: 18.03.2021 um 21:53 Uhr)
https://www.reuters.com/article/us-health-coronavirus-science-idUSKBN2B92U7
-
Corona-Mutationen Das Virus nutzt die Schwachen aus
(Hinzugefügt: 17.03.2021 um 02:08 Uhr)
https://www.spiegel.de/wissenschaft/mensch/corona-menschen-mit-geschwaechtem-immunsystem-sind-offenbar-perfekte-wirte-fuer-das-coronavirus-a-78d1c66f-2b32-4373-b64e-a31cc92a6159
-
An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status
(Hinzugefügt: 15.03.2021 um 15:08 Uhr)
https://www.medrxiv.org/content/10.1101/2021.03.09.21253218v1
-
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
(Hinzugefügt: 13.03.2021 um 07:49 Uhr)
https://www.cell.com/cell/fulltext/S0092-8674(21)00298-1?rss=yes
-
The great escape? SARS-CoV-2 variants evading neutralizing responses
(Hinzugefügt: 12.03.2021 um 06:36 Uhr)
https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(21)00089-5
-
Immunity to SARS-CoV-2 variants of concern
(Hinzugefügt: 12.03.2021 um 06:20 Uhr)
https://science.sciencemag.org/content/371/6534/1103.full
-
Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination
(Hinzugefügt: 09.03.2021 um 13:19 Uhr)
https://dash.harvard.edu/bitstream/handle/1/37366988/Dose_sparing_evolution.pdf?sequence=1&isAllowed=y
-
Mutationen schwächen auch die Immunantwort durch T-Killerzellen
(Hinzugefügt: 08.03.2021 um 09:25 Uhr)
https://www.20min.ch/story/mutationen-schwaechen-auch-die-immunantwort-durch-t-killerzellen-719303598507
-
How the different Covid vaccines will handle new variants of the virus
(Hinzugefügt: 07.03.2021 um 08:14 Uhr)
https://www.cnbc.com/2021/03/05/how-the-different-covid-vaccines-will-handle-variants.html
-
Virologe besorgt Mutationen könnten Teilimmunität nutzen
(Hinzugefügt: 06.03.2021 um 09:42 Uhr)
https://www.n-tv.de/panorama/Mutationen-koennten-Teilimmunitaet-nutzen-article22406858.html
-
New evidence COVID-19 antibodies, vaccines less effective against variants
(Hinzugefügt: 06.03.2021 um 08:10 Uhr)
https://medicine.wustl.edu/news/new-evidence-covid-19-antibodies-vaccines-less-effective-against-variants/
-
Großbritannien will Zulassung angepasster Impfstoffe beschleunigen
(Hinzugefügt: 05.03.2021 um 06:50 Uhr)
https://www.aerzteblatt.de/nachrichten/121752/Grossbritannien-will-Zulassung-angepasster-Impfstoffe-beschleunigen
-
ACCESS Consortium guidance on strain changes in authorised COVID-19 vaccines
(Hinzugefügt: 04.03.2021 um 15:25 Uhr)
https://www.gov.uk/government/publications/access-consortium-guidance-on-strain-changes-in-authorised-covid-19-vaccines
-
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines
(Hinzugefügt: 04.03.2021 um 08:11 Uhr)
https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(21)00102-5
-
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
(Hinzugefügt: 04.03.2021 um 08:06 Uhr)
https://www.nature.com/articles/s41591-021-01285-x.epdf?sharing_token=K_ehhjbEX5xnSDreP85Bx9RgN0jAjWel9jnR3ZoTv0PHrWGE1ztRK1Cl8-gyfXxc2yIVk-fIWCgfjx90gIFEtbWZrnv7a9KCSgobGE1-pF1SjGBgQWZQlDWvq3J87g3yfTVBoIVqIJH02yhlnziR_8yHVHzwFoeNEaSveOoPMgc%3D
-
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
(Hinzugefügt: 03.03.2021 um 08:30 Uhr)
https://www.nature.com/articles/s41591-021-01285-x
-
Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees.
(Hinzugefügt: 03.03.2021 um 08:23 Uhr)
https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1
-
Assessing the human immune response to SARS-CoV-2 variants
(Hinzugefügt: 02.03.2021 um 06:49 Uhr)
https://www.nature.com/articles/s41591-021-01290-0
-
Covid-19 variants pose 'real threat' to vaccine progress, CDC warns
(Hinzugefügt: 02.03.2021 um 06:48 Uhr)
https://www.bbc.com/news/world-us-canada-56247656
-
Will Delaying Vaccine Doses Cause a Coronavirus Escape Mutant?
(Hinzugefügt: 28.02.2021 um 07:30 Uhr)
https://www.the-scientist.com/news-opinion/will-delaying-vaccine-doses-cause-a-coronavirus-escape-mutant--68424
-
The CIDRAP Viewpoint Reassessing COVID-19 Vaccine Deployment in Anticipation of a US B.1.1.7 Surge: Stay the Course or Pivot?
(Hinzugefügt: 28.02.2021 um 07:30 Uhr)
https://www.cidrap.umn.edu/sites/default/files/public/downloads/cidrap-covid19-viewpoint-report7.pdf
-
Is It Safe to Delay a Second COVID Vaccine Dose?
(Hinzugefügt: 28.02.2021 um 07:29 Uhr)
https://www.scientificamerican.com/article/is-it-safe-to-delay-a-second-covid-vaccine-dose/
-
South Africa Has Concerns About Sputnik V, Novavax Vaccines Read more at: https://www.bloombergquint.com/business/south-africa-has-concerns-about-sputnik-v-novavax-vaccines
(Hinzugefügt: 26.02.2021 um 03:32 Uhr)
https://www.bloombergquint.com/business/south-africa-has-concerns-about-sputnik-v-novavax-vaccines
-
Evidence of escape of SARS-CoV-2 variant B.1.351 (South Africa) from natural and vaccine induced sera. An analysis of AstraZeneca, Pfizer, Novavax and Janssen vaccine efficacy.
(Hinzugefügt: 26.02.2021 um 03:32 Uhr)
https://www.regenhealthsolutions.info/2021/02/24/evidence-of-escape-of-sars-cov-2-variant-b-1-351-south-africa-from-natural-and-vaccine-induced-sera-an-analysis-of-astrazeneca-pfizer-novavax-and-janssen-vaccine-efficacy/
-
Adapting COVID-19 vaccines to SARS-CoV-2 variants: guidance for vaccine manufacturers
(Hinzugefügt: 26.02.2021 um 03:29 Uhr)
https://www.ema.europa.eu/en/news/adapting-covid-19-vaccines-sars-cov-2-variants-guidance-vaccine-manufacturers
-
Wann kommt ein Impfstoff gegen die mutierten Viren?
(Hinzugefügt: 25.02.2021 um 19:28 Uhr)
https://www.dw.com/de/wann-kommt-ein-impfstoff-gegen-die-mutierten-viren/a-56664421
-
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera
(Hinzugefügt: 24.02.2021 um 08:46 Uhr)
https://www.cell.com/action/showPdf?pii=S0092-8674%2821%2900226-9
-
Coronavirus (COVID-19) Update: FDA Issues Policies to Guide Medical Product Developers Addressing Virus Variants
(Hinzugefügt: 23.02.2021 um 08:53 Uhr)
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-policies-guide-medical-product-developers-addressing-virus
-
Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
(Hinzugefügt: 18.02.2021 um 13:37 Uhr)
https://www.medrxiv.org/content/10.1101/2021.02.14.21251704v1
-
Von der Leyens zweiter Impfstoffanlauf Diesmal muss es funktionieren
(Hinzugefügt: 18.02.2021 um 07:55 Uhr)
https://www.spiegel.de/politik/deutschland/kampf-gegen-corona-mutanten-ursula-von-der-leyen-stellt-fuenf-punkte-plan-vor-a-d4e40821-a3e1-412a-8b1d-6c7aa0c53d8d
-
Virusmutationen: EMA will veränderte Impfstoffe schneller zulassen
(Hinzugefügt: 17.02.2021 um 08:40 Uhr)
https://www.aerzteblatt.de/nachrichten/121180/Virusmutationen-EMA-will-veraenderte-Impfstoffe-schneller-zulassen
-
How ‘killer’ T cells could boost COVID immunity in face of new variants
(Hinzugefügt: 13.02.2021 um 13:18 Uhr)
https://www.nature.com/articles/d41586-021-00367-7
-
Variant-proof vaccines — invest now for the next pandemic
(Hinzugefügt: 12.02.2021 um 08:56 Uhr)
https://www.nature.com/articles/d41586-021-00340-4
-
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
(Hinzugefügt: 11.02.2021 um 12:34 Uhr)
https://www.nature.com/articles/s41586-021-03324-6#article-info
-
Covid-19: The E484K mutation and the risks it poses
(Hinzugefügt: 10.02.2021 um 09:49 Uhr)
https://www.bmj.com/content/372/bmj.n359
-
Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies
(Hinzugefügt: 09.02.2021 um 09:12 Uhr)
https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
-
Evolution of Antibody Immunity to SARS-CoV-2
(Hinzugefügt: 07.02.2021 um 15:50 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654855/
-
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
(Hinzugefügt: 07.02.2021 um 15:49 Uhr)
https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2
-
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
(Hinzugefügt: 07.02.2021 um 15:49 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723407/
-
Mutation B117 wird gefährlicher Forschungsteam weist verminderte Impfstoffwirkung nach
(Hinzugefügt: 06.02.2021 um 09:38 Uhr)
https://www.tagesspiegel.de/wissen/mutation-b117-wird-gefaehrlicher-forschungsteam-weist-verminderte-impfstoffwirkung-nach/26875978.html
-
New Study of Coronavirus Variants Predicts Virus Evolving to Escape Current Vaccines, Treatments
(Hinzugefügt: 06.02.2021 um 09:33 Uhr)
https://www.cuimc.columbia.edu/news/new-study-coronavirus-variants-predicts-virus-evolving-escape-current-vaccines-treatments
-
SARS-CoV-2 evolution and vaccines: cause for concern?
(Hinzugefügt: 01.02.2021 um 08:31 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00075-8/fulltext